-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on C4 Therapeutics, Lowers Price Target to $5

Benzinga·12/17/2025 17:36:02
语音播报
Barclays analyst Etzer Darout maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and lowers the price target from $10 to $5.